<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422627</url>
  </required_header>
  <id_info>
    <org_study_id>20160283</org_study_id>
    <secondary_id>2017-000763-33</secondary_id>
    <nct_id>NCT03422627</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease</brief_title>
  <official_title>A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 592 inAdult Subjects With Steroid Refractory Chronic Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b To evaluate the safety and tolerability of multiple ascending doses of AMG 592 in
      subjects with steroid refractory cGVHD.

      Phase 2 To evaluate the efficacy of AMG 592 in subjects with steroid refractory cGVHD as
      measured by ORR at 16 weeks according to the 2014 cGVHD NIH Consensus Criteria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Incidence of dose limiting toxicities</measure>
    <time_frame>4 weeks following first dose per subject</time_frame>
    <description>Calculate incidence of dose limiting toxicities (DLT's) for all subjects who complete the 4 weeks following their first dose of AMG 592 within each cohort. To be evaluable for a DLT subjects must have received at least 2 doses of AMG 592 or have experienced a DLT within the DLT evaluation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Incidence of all treatment-related and treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluate safety of AMG 592</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Best overall response rate defined as the proportion of subjects achieving a Complete Response (CR) or Partial Response (PR) during the study according to the 2014 cGVHD NIH Consensus Criteria</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluate efficacy as measured by the best overall response rate during the study according to the 2014 cGVHD National Institutes of Health Consensus Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Incidence of treatment-emergent and treatment-related and treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluate safety of AMG 592</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Failure free survival rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluate failure free survival, defined as absence of relapse, death, or need for additional systemic immunosuppressant cGVHD therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Changes in symptom burden over time</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluate changes in symptom burden as measured by the Lee Symptom Scale. A change of 6 to 7 points on the Lee Symptom Scale will be considered clinically significant and relates to improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Changes in quality of life</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measure changes in quality of life as measured by Short Form Health Survey 36 version 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Changes in quality of life</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measure changes in quality of life as measured by Karnofsky performance status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Chronic Graft Versus Host Disease cGVHD</condition>
  <arm_group>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase 1b portion of this study will be conducted as a multiple ascending dose study. Each dosing cohort will consist of 3 subjects who will receive either weekly or biweekly AMG 592 plus protocol permitted background therapy for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase 2 portion of this study will be conducted as a single arm, multi-center, open‑label trial in subjects with steroid refractory cGVHD. All subjects will receive the recommended phase 2 dose of AMG 592 for up to 52 plus protocol permitted background therapy for cGVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 592</intervention_name>
    <description>Phase 1b Each dosing cohort will receive either weekly or biweekly AMG 592 for up to 52 weeks.
Phase 2 All subjects will receive the recommended phase 2 dose of AMG 592 for up to 52 weeks.</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or Female ≥ 18 years old at the time of signing the informed consent.

          -  Recipient of an allogeneic HSCT.

          -  Moderate to severe steroid-refractory cGVHD as defined by all following criteria:

               -  Diagnosed with cGVHD per the 2014 cGVHD NIH Consensus Criteria(Jagasia, 2015;
                  Appendix 8) within the past 2 years prior to screening.

               -  Steroid refractory cGVHD, defined as having persistent signs and symptoms of
                  cGVHD despite ≥ 4 weeks of prednisone (or equivalent) dosed at ≥ 0.25 mg/kg/day
                  (or ≥ 0.5 mg/kg every other day) within the 12 months prior to screening.

               -  Moderate to severe cGVHD (in accordance with 2014 cGVHD NIH Consensus Criteria
                  [Jagasia, 2015; Appendix 9]) at screening with involvement of at least one of the
                  following organs at the screening and baseline visits: skin, mouth, eyes,
                  gastrointestinal (GI) tract, liver, lungs, and joint and fascia.

          -  No more than 3 previous treatments for cGVHD, excluding topical agents.

          -  Stable dose of ≤ 1 mg/kg/day of systemic prednisone or equivalent for at least 2 weeks
             prior to first dose of AMG 592.

          -  Stable dose of non-corticosteroid immunosuppressants for the 2 weeks prior to first
             dose of AMG 592.

          -  Karnofsky performance status score ≥ 50%.

          -  Adequate bone marrow function indicated by ANC &gt; 1.00 x 109/L and platelets &gt; 50 x
             109/L without growth factors or transfusions within the 4 weeks prior to starting AMG
             592.

        Key Exclusion Criteria:

          -  Concurrently receiving treatment with calcineurin-inhibitor plus sirolimus (either
             agent alone is acceptable).

          -  Received ibrutinib or following therapies considered investigational for treatment of
             cGVHD including imatinib, bortezomib, ruxolitnib, or entospletinib, within 4 wks prior
             to starting AMG 592 or is currently receiving treatment in another investigational
             drug or device study.

          -  Treatment with T-cell depleting, B-cell depleting or IL-2 signaling targeted
             medication (eg, ATG, alemtuzumab, basiliximab, denileukin diftitox, IL-2, rituximab
             within 12wks prior to starting AMG 592.

          -  Treatment with T regulatory cell expanding therapies (ie ECP, PUVA, UVB, adoptively
             transferred T regulatory cells) within 4 wks prior to starting dose of AMG 592.

          -  Donor lymphocyte infusion within 12 wks prior to starting dose of AMG 592.

          -  Active morphologic relapse/progression of hematologic malignancy post transplantation.

          -  History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic
             thrombocytopenic purpura.

          -  Active infection requiring treatment with IV antibiotics or hospitalized for treatment
             of an active infection in 4 wks prior to starting dose of AMG 592.

          -  History of active tuberculosis.

          -  Hep B and Hep C

          -  HIV-positive.

          -  Phase 1b subject has a positive drug or alcohol urine test at screening visit.

          -  Phase 1b subject is unable to avoid alcohol or tobacco consumption for the duration of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

